Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Radiology

The Diagnostic Process: Imaging and Biopsy

At a Glance

Breast fibroadenoma diagnosis combines a clinical exam with age-appropriate imaging, and a core needle biopsy when findings are suspicious or unclear. A benign biopsy is most reassuring when it matches the imaging and exam; discordance may require more testing or excision.

Confirming a fibroadenoma requires more than just a physical exam. Doctors use a standardized framework called the Triple Assessment to ensure an accurate diagnosis [1][2]. This three-part check—clinical exam, imaging, and tissue sampling—is a vital approach for evaluating any breast lump [1]. However, biopsy is not mandatory for every classic, benign-appearing fibroadenoma, particularly in younger patients.

The Role of Imaging

Imaging allows doctors to see the internal structure of the lump. The choice of tool depends largely on your age, symptoms, breast density, and risk:

  • Ultrasound: Ultrasound is generally the initial step for patients under 30 because their breast tissue is often dense, making mammograms harder to read [3][4]. A typical fibroadenoma appears as an oval, circumscribed (well-defined edges), and parallel (wider-than-tall) solid mass [5][6].
  • Mammography and Tomosynthesis: Patients aged 30 to 39 may need ultrasound plus diagnostic mammography or tomosynthesis. For patients 40 and older, diagnostic mammography or tomosynthesis is usually the starting point, often followed by targeted ultrasound [3].

Decoding Your BI-RADS Score

Radiologists use the BI-RADS (Breast Imaging-Reporting and Data System) score to summarize their level of concern [5].

  • BI-RADS 2 (Benign): A definitive benign finding returning to routine screening.
  • BI-RADS 3 (Probably Benign): This score is a population-based estimate meaning there is less than a 2% chance the lump is cancer; the mass is probably benign and likely a fibroadenoma [7][8]. Instead of an immediate biopsy, these are often managed with “short-interval follow-up”—repeat imaging in 6 months to ensure the lump isn’t changing [9][10]. Note that clinical-imaging concordance is important here, and a changing or clinically suspicious mass still needs reassessment despite a BI-RADS 3 label.
  • BI-RADS 4 (Suspicious): This score means the risk is higher than 2%, and a biopsy is recommended to get a definitive answer [7][11]. BI-RADS 4 is further divided into 4A (low suspicion), 4B (moderate), and 4C (high) [7].

The Core Needle Biopsy

If your mass requires tissue sampling, you will likely undergo a core needle biopsy. Under a local anesthetic, the doctor uses a hollow needle to take small samples of the tissue. You may feel pressure, and bruising afterward is common. The doctor will often place a tiny metallic marker clip at the site so it can be easily identified on future scans, and your results are typically communicated a few days later.

The Importance of “Concordance”

If a biopsy is performed, your care team will look for concordance. This means the biopsy results (pathology) match what the doctor saw on the imaging and during the exam [12][13]. A benign result is reassuring only when it is radiologically and clinically concordant.

  • Concordant Results: If the imaging looked like a fibroadenoma and the biopsy confirmed it is a fibroadenoma, the diagnosis is concordant, and you can safely move to observation [14][15].
  • Discordant Results: If the biopsy says “benign” but the imaging looked “highly suspicious,” the results are discordant [16]. In these cases, a doctor may recommend a repeat biopsy or surgical removal (excision) because the small needle sample might have missed the more concerning part of the lump [16][17].

Reading the Pathology Report

Your pathology report may contain technical terms that describe the specific “personality” of your fibroadenoma:

  • Fibroepithelial Lesion: A broad category that includes both fibroadenomas and phyllodes tumors [18]. Doctors use this term when a small biopsy sample isn’t enough to tell them apart [19].
  • Cellular Fibroepithelial Lesion: This is a descriptive core-biopsy category, not a diagnosis of phyllodes tumor. Because this can be a sign of a faster-growing mass, doctors may recommend excision to be certain of the diagnosis, depending on stromal cellularity, imaging, size, growth, and sampling adequacy [19][20].
  • Complex Fibroadenoma: A fibroadenoma is labeled “complex” if it contains specific microscopic features, such as cysts larger than 3mm, sclerosing adenosis (extra tissue growth in the breast’s small lobules), calcifications, or papillary apocrine metaplasia (a type of cell change) [21]. While these features sound complex, they are still benign findings, and the exact wording and radiology-pathology correlation determine management [21].

Common questions in this guide

How is a breast fibroadenoma diagnosed?
Doctors use a triple assessment that combines a clinical breast exam, imaging, and tissue sampling when needed. A biopsy may not be necessary when the lump has classic benign features, particularly in a younger patient.
Which imaging test is used to evaluate a breast fibroadenoma?
Ultrasound is generally the first test for patients younger than 30. Patients ages 30 to 39 may have ultrasound plus diagnostic mammography or tomosynthesis, while diagnostic mammography or tomosynthesis is often the starting point at age 40 and older, followed by targeted ultrasound when needed.
What does BI-RADS 3 mean for a breast lump?
BI-RADS 3 means the finding is probably benign, with a less than 2% chance of cancer based on population data. Instead of immediate biopsy, doctors often recommend repeat imaging in about 6 months, although a growing or clinically suspicious lump needs reassessment.
Why might a BI-RADS 4 breast lump need a biopsy?
BI-RADS 4 means the finding has a cancer risk higher than 2%, so a core needle biopsy is generally recommended to obtain a definite tissue diagnosis. The category is divided into 4A, 4B, and 4C to describe low, moderate, or high suspicion.
What does concordance mean after a fibroadenoma biopsy?
Concordance means the biopsy result matches what the doctor saw on imaging and during the clinical examination. A benign result is most reassuring when it is concordant; if the result is benign but the imaging is highly suspicious, repeat biopsy or surgical excision may be recommended.
What do cellular fibroepithelial lesion and complex fibroadenoma mean?
A fibroepithelial lesion is a broad category that includes fibroadenomas and phyllodes tumors, while a cellular fibroepithelial lesion is a descriptive biopsy finding rather than a diagnosis of phyllodes tumor. Excision may be recommended when the sample cannot establish the diagnosis with confidence. A complex fibroadenoma contains features such as larger cysts, sclerosing adenosis, calcifications, or papillary apocrine metaplasia; these features are benign, but the full report and imaging correlation guide management.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my imaging report use the term 'circumscribed' and 'parallel' to describe the lump?
  2. 2.My BI-RADS score is [3/4]; based on that, why are we choosing [monitoring/biopsy] as the next step?
  3. 3.Did the radiologist and pathologist confirm that my biopsy results are 'concordant' with my imaging?
  4. 4.Does my pathology report mention any 'complex' features like cysts larger than 3mm or sclerosing adenosis?
  5. 5.If my report says 'cellular fibroepithelial lesion,' why is a surgical excision being recommended instead of monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Correlation of Histopathology and Radiological Findings Among the Diverse Breast Lesions in a Tertiary Care Centre.

    Mohan R, Selvakumar A S, S R, et al.

    Cureus 2024; (16(1)):e52097 doi:10.7759/cureus.52097.

    PMID: 38344545
  2. 2

    ACR Appropriateness Criteria® Palpable Breast Masses.

    , Moy L, Heller SL, et al.

    Journal of the American College of Radiology : JACR 2017; (14(5S)):S203-S224 doi:10.1016/j.jacr.2017.02.033.

    PMID: 28473077
  3. 3

    ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update.

    , Klein KA, Kocher M, et al.

    Journal of the American College of Radiology : JACR 2023; (20(5S)):S146-S163 doi:10.1016/j.jacr.2023.02.013.

    PMID: 37236740
  4. 4

    ACR Appropriateness Criteria Palpable Breast Masses.

    Harvey JA, Mahoney MC, Newell MS, et al.

    Journal of the American College of Radiology : JACR 2016; (13(11S)):e31-e42 doi:10.1016/j.jacr.2016.09.022.

    PMID: 27814822
  5. 5

    Understanding BI-RADS Category 3.

    Fazeli S, Stepenosky J, Guirguis MS, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240169 doi:10.1148/rg.240169.

    PMID: 39636752
  6. 6

    Diagnostic performance of ultrasound strain elastography for differentiation of malignant breast lesions.

    Georgieva M, Prantl L, Utpatel K, et al.

    Clinical hemorheology and microcirculation 2019; (71(2)):237-247 doi:10.3233/CH-189415.

    PMID: 30584133
  7. 7

    Utility of BI-RADS Assessment Category 4 Subdivisions for Screening Breast MRI.

    Strigel RM, Burnside ES, Elezaby M, et al.

    AJR. American journal of roentgenology 2017; (208(6)):1392-1399 doi:10.2214/AJR.16.16730.

    PMID: 28792802
  8. 8

    The Positive Predictive Values of the Breast Imaging Reporting and Data System (BI-RADS) 4 Lesions and its Mammographic Morphological Features.

    Mohapatra SK, Mishra A, Sahoo TK, et al.

    Indian journal of surgical oncology 2021; (12(1)):182-189 doi:10.1007/s13193-020-01274-5.

    PMID: 33814852
  9. 9

    Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.

    Berg WA, Berg JM, Sickles EA, et al.

    Radiology 2020; (296(1)):32-41 doi:10.1148/radiol.2020192641.

    PMID: 32427557
  10. 10

    Follow-up Recommendations for Young, Average Risk Women With BI-RADS 3 Masses.

    Shpanskaya K, Nguyen DL, Grimm LJ, Ghate SV

    Journal of breast imaging 2026; (8(1)):22-31 doi:10.1093/jbi/wbaf042.

    PMID: 41217444
  11. 11

    Nonpalpable BI-RADS 4 breast lesions: sonographic findings and pathology correlation.

    Elverici E, Barça AN, Aktaş H, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2015; (21(3)):189-94 doi:10.5152/dir.2014.14103.

    PMID: 25835079
  12. 12

    Evaluating imaging-pathology concordance and discordance after ultrasound-guided breast biopsy.

    Park VY, Kim EK, Moon HJ, et al.

    Ultrasonography (Seoul, Korea) 2018; (37(2)):107-120 doi:10.14366/usg.17049.

    PMID: 29169231
  13. 13

    Demystifying Breast Disease Markers.

    Wells VA, Medeiros I, Shevtsov A, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2023; (43(10)):e220151 doi:10.1148/rg.220151.

    PMID: 37676826
  14. 14

    Imaging and Management of Fibroepithelial Lesions of the Breast: Radiologic-Pathologic Correlation.

    Zhang M, Arjmandi FK, Porembka JH, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2023; (43(11)):e230051 doi:10.1148/rg.230051.

    PMID: 37856317
  15. 15

    American Society of Breast Surgeons and Society of Breast Imaging 2025 Guidelines for the Management of Benign Breast Fibroepithelial Lesions.

    Rosenberger LH, White RL, Tafra L, et al.

    JAMA surgery 2025; (160(12)):1378-1385 doi:10.1001/jamasurg.2025.4392.

    PMID: 41123921
  16. 16

    Radiologic-Pathologic Discordance After Image-Guided Breast Biopsy: A Systematic Review of Prevalence and Outcomes.

    Yincharoen P, Sharma CP, Tawanwongsri W

    Medical sciences (Basel, Switzerland) 2026; (14(2)) doi:10.3390/medsci14020229.

    PMID: 42201021
  17. 17

    Role of ultrasound-guided vacuum-assisted breast biopsy in the management of radiologic-pathologic discordance: a retrospective single-centre study.

    Vatteroni G, Pinna G, Trimboli RM, et al.

    La Radiologia medica 2024; (129(10)):1454-1462 doi:10.1007/s11547-024-01864-1.

    PMID: 39102107
  18. 18

    Fibroepithelial Lesions: An Update for Daily Practice (Part-I).

    Long Chow Z, Gudi M, Tan PH

    Surgical pathology clinics 2025; (18(4)):675-699 doi:10.1016/j.path.2025.05.005.

    PMID: 41224412
  19. 19

    Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management.

    Rakha EA, Quinn C, Raymond W, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(5)):100734 doi:10.1016/j.modpat.2025.100734.

    PMID: 39947480
  20. 20

    Which lesions with a radiological or core biopsy diagnosis of fibroadenoma should be excised?

    Lee A, James J, Whisker L, et al.

    Annals of the Royal College of Surgeons of England 2022; (104(5)):361-366 doi:10.1308/rcsann.2021.0208.

    PMID: 34939848
  21. 21

    Carcinoma Breast-Like Giant Complex Fibroadenoma: A Clinical Masquerade.

    Nigam JS, Tewari P, Prasad T, et al.

    Cureus 2021; (13(1)):e12611 doi:10.7759/cureus.12611.

    PMID: 33585101

This page explains imaging and biopsy for breast fibroadenoma for informational purposes only and does not constitute medical advice. Your radiologist, pathologist, and treating clinician should interpret your results and recommend next steps.

Get notified when new evidence is published on breast fibroadenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.